Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TARBP2 | Q15633 | 7/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | PDCD4 | Q53EL6 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27189076 | 0.97 | TARBP2 (0.78) | TARBP2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7699490 | 0.95 | TARBP2 (0.67) | TARBP2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7701292 | 0.92 | TARBP2 (0.67) | TARBP2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29158677 | 0.91 | TARBP2 (0.72) | TARBP2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL16005699 | 0.91 | TARBP2 (0.72) | TARBP2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7701068 | 0.90 | ALDH1A1 (0.69) | TARBP2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29158615 | 0.90 | TARBP2 (0.65) | TARBP2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29158580 | 0.90 | ALDH1A1 (0.69) | TARBP2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29158624 | 0.90 | TARBP2 (0.65) | TARBP2KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29158792 | 0.89 | TARBP2 (0.63) | TARBP2KDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022255764-A1 | NOVEL OXAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME FOR PREVENTION OR TREATMENT OF ALLERGIC DISEASE | 주식회사 에즈큐리스 | 2022-12-08 | — | — | WO | disclosed |
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
| EP-1315707-A1 | LIPO- OR AMPHIPHILIC SCINTILLATORS AND THEIR USE IN ASSAYS | SENSE PROTEOMIC LIMITED (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-6515015-B1 | In combination with one or more known sulfonylureas, biguanides, alpha -glucosidase inhibitors, other insulin secretogogues or insulin | MERCK & CO. INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1251849-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-30 | — | — | EP | disclosed |
| EP-1251848-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-10-30 | — | — | EP | disclosed |
| WO-2002014290-A1 | LIPO- OR AMPHIPHILIC SCINTILLATORS AND THEIR USE IN ASSAYS | SENSE PROTEOMIC LIMITED (GB) | 2002-02-21 | — | — | WO | disclosed |
| EP-1123327-A1 | SOLID SUPPORTS CONTAINING SCINTILLANT | The Nottingham Trent University (GB) | 2001-08-16 | — | — | EP | disclosed |
| WO-2001052845-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPOATED (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001052846-A1 | GYRASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-07-26 | — | — | WO | disclosed |
| WO-2000020475-A1 | SOLID SUPPORTS CONTAINING SCINTILLANT | THE NOTTINGHAM TRENT UNIVERSITY (GB) | 2000-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | TARBP2 3854/4885KDM4E 1047/4885ALDH1A1 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.